Pankowski and Ferraro’s workers’ compensation lawsuit

Pankowski and Ferraro’s workers’ compensation lawsuit brought the health consequences of Xerxine production before the courts, but it ended in defeat: the workers could not overcome the company’s arguments about causation and the limits of what was known when they were exposed. Later evidence from Xerxes employee medical records made the case look less like an isolated dispute than an early glimpse of a much wider occupational-health problem.

Industrial Exposure and the Workers’ Claims

Xerxine was a chlorinated hydrocarbon solvent made by adding chlorine to ethylene gas. During its production, vapors could affect the liver, kidneys, and central nervous system. When Humboldt Chemical began making the solvent in the 1950s, the risks of such exposure were not well understood and controls were not sufficiently careful to keep the vapors out of the air.

By the 1960s and 1970s, researchers were examining industrial pollution and worker health, and evidence increasingly indicated that chemicals such as Xerxine could be toxic even at low concentrations. Xerxes installed air scrubbers and sealed pipes more effectively; by the late 1970s, its airborne levels had been brought down to the federal standard of fifty parts per million. That later standard did not resolve what earlier exposure had done to workers who had spent years in the plant before the hazards were widely recognized.

Pankowski and Ferraro approached Frederick Manheim in early 1983. Ferraro had worked at Humboldt since 1959 and Pankowski since 1961. Both had become seriously ill and had left their jobs when they could no longer work; Pankowski had liver cancer, and Ferraro had aplastic anemia. They had learned that Xerxine might cause their conditions and hoped to obtain workers’ compensation. Because they had already stopped working, they could not collect disability benefits, and Manheim believed they might not have been told that those benefits were available.

Their position was also shaped by the local labor climate. Xerxes had a single-shop union that Manheim described as largely serving the company, while severe unemployment in the neighborhood discouraged workers from challenging their employer. The claim therefore faced obstacles beyond the medical question: the workers were seeking redress after leaving the plant, with limited knowledge of benefits and little institutional support for pressing their case.

Filing Suit and the Company’s Defense

Manheim first approached the company, but Humboldt Chemical would not negotiate. He moved quickly to file suit because he did not know how long either client would live. If the workers died before a successful resolution, he explained, their families could still be entitled to an indemnity payment; he nevertheless wanted his clients to live to see a victory. An early court date gave the case urgency, but did not solve its evidentiary problem.

Humboldt Chemical argued that the illnesses could not be attributed to Xerxine rather than other exposures. Both men smoked, Pankowski drank heavily, and both had spent their lives in South Chicago, where the surrounding air itself offered a competing explanation. The company also argued that the men had worked at the plant before Xerxine’s toxicity was known, and that the company had operated according to the medical knowledge of the time. The court accepted the company’s position, and the workers lost decisively. A skilled appellate lawyer later advised Manheim that the record offered no viable basis for an appeal.

Threats, Records, and a Wider Pattern

After the case, while an appeal was under consideration, Manheim received a threatening telephone call. The caller did not identify the lawsuit, instead making a general reference to the dangers of using the appellate system. Manheim said the call angered him and that he pursued every possible route toward an appeal, but he could not find a way to build one. He did not take the call to the State’s Attorney’s Office. The threat thus entered the history of the case without producing a successful appeal or a reported prosecution.

Later, medical review of Chigwell’s notebooks expanded the scale of what the lawsuit had addressed. The records included blood histories for Ferraro and Louisa Djiak, as well as approximately five hundred other Xerxes employees, covering 1955 to 1982. Their reported changes in blood measures were consistent with kidney, liver, and bone-marrow dysfunction. Louisa’s records indicated noticeable renal damage by 1967 and severe damage by 1969; she experienced diffuse symptoms around 1979 but attributed them to menopause and did not seek medical care then. Ferraro’s record ended with his death from aplastic anemia in 1983. A specialist’s review also found the blood-chemistry changes consistent with Xerxine exposure.

These records did not erase the evidentiary difficulty that had defeated Pankowski and Ferraro’s claim. They did, however, make the lawsuit’s narrow focus on two clients stand in stark contrast to a company archive documenting health histories for hundreds of employees. The legal defense had relied on alternative causes and on the fact that exposure preceded recognized knowledge of toxicity; the later records supplied a longer view of illness and exposure than the original case had been able to establish.

Consequences and Significance

The lawsuit’s loss also illuminated the difference between a formal right to compensation and a worker’s practical ability to secure it. The clients had left work too sick to continue, did not receive disability benefits, and encountered a company unwilling to settle. In court, the competing explanations for their illnesses and the historical timing of exposure were enough to defeat their claim, even as later records showed a pattern consistent with occupational harm.

The case returned as a possible foundation for broader action when Victoria Warshawski asked Frederick Manheim whether he would organize claims for hundreds of former Xerxes employees, and possibly current workers as well. He recognized that such work could consume the next decade and require researchers, associates, and paralegals, while attracting powerful firms seeking a share of the contingency fees. Remembering the earlier threat and the possibility that the case could now be won, he agreed to take on the work. The available account ends with that commitment, not with a ruling on any subsequent claims.